All In Biotech

Drug Trial Radar · NCT07219420

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Nov 14, 2025

Primary completion

Dec 27, 2027

Study completion Nov 22, 2029

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Oct 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).

Conditions

  • Palmoplantar Pustulosis

Interventions

  • BimekizumabDrug

    Study participants will receive bimekizumab at pre-specified time points.

  • PlaceboDrug

    Study participants will receive matching placebo at pre-specified time points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Palmoplantar pustulosis-Investigator Global Assessment 0/1 (PPP-IGA 0/1) response at Week 16Time frame: At Week 16

Locations

91 sites in 13 countries. Site status is shown where the registry gives one.

  • Ppp001 50754

    Birmingham, Alabama · Recruiting

  • Ppp001 50176

    Fremont, California · Recruiting

  • Ppp001 50746

    Miami, Florida · Recruiting

  • Ppp001 50757

    Auburn Hills, Michigan · Recruiting

  • Ppp001 50745

    Columbus, Ohio · Recruiting

  • Ppp001 50202

    Fairborn, Ohio · Recruiting

  • Ppp001 50733

    Mayfield Heights, Ohio · Recruiting

  • Ppp001 50744

    Oklahoma City, Oklahoma · Recruiting

  • Ppp001 50233

    Barrie, Canada · Recruiting

  • Ppp001 50354

    Calgary, Canada · Recruiting

  • Ppp001 50749

    Fredericton, Canada · Recruiting

  • Ppp001 50765

    London, Canada · Recruiting

  • Ppp001 50740

    Québec, Canada · Recruiting

  • Ppp001 50752

    Red Deer, Canada · Recruiting

  • Ppp001 50750

    Surrey, Canada · Recruiting

  • Ppp001 20357

    Beijing, China · Recruiting

  • Ppp001 20137

    Chengdu, China · Recruiting

  • Ppp001 20352

    Chengdu, China · Recruiting

  • Ppp001 20350

    Chongqing, China · Recruiting

  • Ppp001 20311

    Guangzhou, China · Recruiting

  • Ppp001 20313

    Guangzhou, China · Recruiting

  • Ppp001 20022

    Hangzhou, China · Recruiting

  • Ppp001 20193

    Hangzhou, China · Recruiting

  • Ppp001 20344

    Jinan, China · Recruiting

  • Ppp001 20355

    Jinan, China · Recruiting

  • Ppp001 20345

    Shanghai, China · Recruiting

  • Ppp001 20184

    Shenzhen, China · Recruiting

  • Ppp001 20136

    Tianjin, China · Recruiting

  • Ppp001 20356

    Xi'an, China · Recruiting

  • Ppp001 20353

    Yinchuan, China · Recruiting

  • Ppp001 40748

    Plzen-bory, Czechia · Recruiting

  • Ppp001 40881

    Ústí nad Labem, Czechia · Recruiting

  • Ppp001 40886

    Hellerup, Denmark · Recruiting

  • Ppp001 40067

    Lyon, France · Recruiting

  • Ppp001 40874

    Nice, France · Recruiting

  • Ppp001 40887

    Toulon, France · Recruiting

  • Ppp001 40875

    Ahaus, Germany · Recruiting

  • Ppp001 40740

    Bad Bentheim, Germany · Recruiting

  • Ppp001 40515

    Berlin, Germany · Recruiting

  • Ppp001 40891

    Bielefeld, Germany · Recruiting

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.